View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Peer Walmart 4Q25/26 results. Arcadis: Main topics 4Q25/FY25 conference call. ASM: 4Q25 preview, FY26 should be strong. Brunel: 4Q25 result beats and trends stabilise; DACH back to growth in 1Q26; additional cost savings announced and special dividend. Cofinimmo: Beat on bottom line, strong investment outlook for 2026. IMCD: Another step in EMEA. Magnum Ice Cream Company: Peer Danone 4Q25 results. Recticel: Peer Kingspan FY25 results. Software sector: Cheaper code...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

 PRESS RELEASE

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expan...

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...

 PRESS RELEASE

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre...

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

Guy Sips ... (+3)
  • Guy Sips
  • Mathijs Geerts Danau
  • Wim Hoste
 PRESS RELEASE

Inventiva reports preliminary 2025¹ fiscal year financial results

Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...

 PRESS RELEASE

Inventiva publie ses résultats financiers préliminaires pour l’exercic...

Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹ Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour un produit brut total d’environ 172,5 millions de dollars (149 millions d’euros)3Horizon de trésorerie prévue jusqu’au milieu du premier trimestre 20274 Daix (France), New York City (New York, Etats-Unis), le 17 février 2026 – (Euronext Paris and Nasdaq :IVA) (« Inventiva » ou ...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 16th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 16 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif ...

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Lewi
Lynn Hautekeete
  • Lynn Hautekeete

Home Invest Belgium FY25: Strong Underlying Performance Overshadowed b...

Home Invest reports results in line with our expectations at €1,21 EPRA EPS. It guides €1,23 EPRA EPS in FY26, slightly ahead of our expectation of € 1,20. At 1H25 results, Home Invest confirmed our thesis that the building right in Louvain-La-Neuve will not get renewed. As of the announcement Home Invest started to underperform (-7,1%) the EPRA index (+8,6%). The UCL has time until June 2026 to respond. This headwind will keep EPRA EPS growth muted, despite the stellar operational results: 98,...

 PRESS RELEASE

CMB.TECH ANNOUNCES Q4 2025 RESULTS ON 26/02/2026

CMB.TECH ANNOUNCES Q4 2025 RESULTS ON 26/02/2026 Antwerp, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its fourth quarter 2025 earnings prior to market opening on Thursday 26 February 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.  The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the  of the website. The presentation, recording & transcript will also be available on this page....

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch